11. Januar 2019

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG

11.01.2019 / 10:50
Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer

Name:	Epigenomics AG
Street:	Geneststraße 5
Postal code:	10829
City:	Berlin Germany
Legal Entity Identifier (LEI):	549300X1C4U862NDLN97

2. Reason for notification

X	Acquisition/disposal of shares with voting rights
	Acquisition/disposal of instruments
	Change of breakdown of voting rights
	Other reason:

3. Details of person subject to the notification obligation

Legal entity: Morgan Stanley
City of registered office, country: Wilmington, Delaware, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.

Morgan Stanley & Co. LLC

5. Date on which threshold was crossed or reached:

04 Jan 2019

6. Total positions

	% of voting rights attached to shares (total of 7.a.)	% of voting rights through instruments (total of 7.b.1 + 7.b.2)	Total of both in % (7.a. + 7.b.)	Total number of voting rights pursuant to Sec. 41 WpHG
New	3.75 %	0.13 %	3.88 %	36021540
Previous notification	2.78 %	0.13 %	2.91 %	/

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)

ISIN	Absolute		In %
	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)
DE000A11QW50	0	1350000	0.00 %	3.75 %
Total	1350000		3.75 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Voting rights absolute	Voting rights in %
Right of recall over securities lending agreements	at any time	at any time	45919	0.13 %
		Total	45919	0.13 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Cash or physical settlement	Voting rights absolute	Voting rights in %
				0	0.00 %
			Total	0	0.00 %

8. Information in relation to the person subject to the notification obligation

	Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X	Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name	% of voting rights (if at least 3% or more)	% of voting rights through instruments (if at least 5% or more)	Total of both (if at least 5% or more)
Morgan Stanley	%	%	%
Morgan Stanley Capital Management, LLC	%	%	%
Morgan Stanley Domestic Holdings, Inc.	%	%	%
Morgan Stanley & Co. LLC	3.75 %	%	%

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:

Proportion of voting rights	Proportion of instruments	Total of both
%	%	%

10. Other explanatory remarks:

Date

10 Jan 2019

11.01.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Germany
Internet:	www.epigenomics.com


End of News	DGAP News Service

11. Januar 2019

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG

11.01.2019 / 10:47
Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer

Name:	Epigenomics AG
Street:	Geneststraße 5
Postal code:	10829
City:	Berlin Germany
Legal Entity Identifier (LEI):	549300X1C4U862NDLN97

2. Reason for notification

X	Acquisition/disposal of shares with voting rights
	Acquisition/disposal of instruments
	Change of breakdown of voting rights
	Other reason:

3. Details of person subject to the notification obligation

Legal entity: Morgan Stanley
City of registered office, country: Wilmington, Delaware, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.

5. Date on which threshold was crossed or reached:

03 Jan 2019

6. Total positions

	% of voting rights attached to shares (total of 7.a.)	% of voting rights through instruments (total of 7.b.1 + 7.b.2)	Total of both in % (7.a. + 7.b.)	Total number of voting rights pursuant to Sec. 41 WpHG
New	2.78 %	0.13 %	2.91 %	36021540
Previous notification	3.75 %	0.13 %	3.88 %	/

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)

ISIN	Absolute		In %
	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)
DE000A11QW50	0	1002882	0.00 %	2.78 %
Total	1002882		2.78 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Voting rights absolute	Voting rights in %
Right of recall over securities lending agreements	at any time	at any time	45919	0.13 %
		Total	45919	0.13 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Cash or physical settlement	Voting rights absolute	Voting rights in %
				0	0.00 %
			Total	0	0.00 %

8. Information in relation to the person subject to the notification obligation

	Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X	Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name	% of voting rights (if at least 3% or more)	% of voting rights through instruments (if at least 5% or more)	Total of both (if at least 5% or more)
Morgan Stanley	%	%	%
Morgan Stanley Capital Management, LLC	%	%	%
Morgan Stanley Domestic Holdings, Inc.	%	%	%
Morgan Stanley & Co. LLC	%	%	%

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:

Proportion of voting rights	Proportion of instruments	Total of both
%	%	%

10. Other explanatory remarks:

Date

09 Jan 2019

11.01.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Germany
Internet:	www.epigenomics.com


End of News	DGAP News Service

11. Januar 2019

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG

11.01.2019 / 10:50
Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer

Name:	Epigenomics AG
Street:	Geneststraße 5
Postal code:	10829
City:	Berlin Germany
Legal Entity Identifier (LEI):	549300X1C4U862NDLN97

2. Reason for notification

X	Acquisition/disposal of shares with voting rights
	Acquisition/disposal of instruments
	Change of breakdown of voting rights
	Other reason:

3. Details of person subject to the notification obligation

Legal entity: Morgan Stanley
City of registered office, country: Wilmington, Delaware, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.

Morgan Stanley & Co. LLC

5. Date on which threshold was crossed or reached:

04 Jan 2019

6. Total positions

	% of voting rights attached to shares (total of 7.a.)	% of voting rights through instruments (total of 7.b.1 + 7.b.2)	Total of both in % (7.a. + 7.b.)	Total number of voting rights pursuant to Sec. 41 WpHG
New	3.75 %	0.13 %	3.88 %	36021540
Previous notification	2.78 %	0.13 %	2.91 %	/

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)

ISIN	Absolute		In %
	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)
DE000A11QW50	0	1350000	0.00 %	3.75 %
Total	1350000		3.75 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Voting rights absolute	Voting rights in %
Right of recall over securities lending agreements	at any time	at any time	45919	0.13 %
		Total	45919	0.13 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Cash or physical settlement	Voting rights absolute	Voting rights in %
				0	0.00 %
			Total	0	0.00 %

8. Information in relation to the person subject to the notification obligation

	Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X	Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name	% of voting rights (if at least 3% or more)	% of voting rights through instruments (if at least 5% or more)	Total of both (if at least 5% or more)
Morgan Stanley	%	%	%
Morgan Stanley Capital Management, LLC	%	%	%
Morgan Stanley Domestic Holdings, Inc.	%	%	%
Morgan Stanley & Co. LLC	3.75 %	%	%

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:

Proportion of voting rights	Proportion of instruments	Total of both
%	%	%

10. Other explanatory remarks:

Date

10 Jan 2019

11.01.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Germany
Internet:	www.epigenomics.com


End of News	DGAP News Service

11. Januar 2019

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG

11.01.2019 / 10:47
Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer

Name:	Epigenomics AG
Street:	Geneststraße 5
Postal code:	10829
City:	Berlin Germany
Legal Entity Identifier (LEI):	549300X1C4U862NDLN97

2. Reason for notification

X	Acquisition/disposal of shares with voting rights
	Acquisition/disposal of instruments
	Change of breakdown of voting rights
	Other reason:

3. Details of person subject to the notification obligation

Legal entity: Morgan Stanley
City of registered office, country: Wilmington, Delaware, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.

5. Date on which threshold was crossed or reached:

03 Jan 2019

6. Total positions

	% of voting rights attached to shares (total of 7.a.)	% of voting rights through instruments (total of 7.b.1 + 7.b.2)	Total of both in % (7.a. + 7.b.)	Total number of voting rights pursuant to Sec. 41 WpHG
New	2.78 %	0.13 %	2.91 %	36021540
Previous notification	3.75 %	0.13 %	3.88 %	/

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)

ISIN	Absolute		In %
	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)
DE000A11QW50	0	1002882	0.00 %	2.78 %
Total	1002882		2.78 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Voting rights absolute	Voting rights in %
Right of recall over securities lending agreements	at any time	at any time	45919	0.13 %
		Total	45919	0.13 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Cash or physical settlement	Voting rights absolute	Voting rights in %
				0	0.00 %
			Total	0	0.00 %

8. Information in relation to the person subject to the notification obligation

	Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X	Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name	% of voting rights (if at least 3% or more)	% of voting rights through instruments (if at least 5% or more)	Total of both (if at least 5% or more)
Morgan Stanley	%	%	%
Morgan Stanley Capital Management, LLC	%	%	%
Morgan Stanley Domestic Holdings, Inc.	%	%	%
Morgan Stanley & Co. LLC	%	%	%

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:

Proportion of voting rights	Proportion of instruments	Total of both
%	%	%

10. Other explanatory remarks:

Date

09 Jan 2019

11.01.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Germany
Internet:	www.epigenomics.com


End of News	DGAP News Service

07. Januar 2019

Epigenomics AG gibt positive Ergebnisse eines Mikrosimulationsmodells bekannt

DGAP-News: Epigenomics AG / Schlagwort(e): Wissenschaftl. Publikation/Sonstiges

07.01.2019 / 07:45
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

Epigenomics AG gibt positive Ergebnisse eines Mikrosimulationsmodells bekannt

Berlin (Deutschland) und San Diego, CA (USA), 7. Januar 2019 – Die Epigenomics AG (FSE: ECX, OTCQX: EPGNY) gibt bekannt, dass ein Mikrosimulationsmodell, das von externen wissenschaftlichen Experten erstellt wurde, positive Ergebnisse für den Bluttest Epi proColon(R) nachgewiesen hat. Das wissenschaftliche Manuskript wird derzeit finalisiert und in Kürze zur Veröffentlichung eingereicht. Epigenomics wird sich nach der Veröffentlichung des Manuskripts zu den spezifischen Ergebnissen äußern.

Mikrosimulationsmodelle werden verwendet, um die Auswirkung und den Nutzen verschiedener Strategien für die Früherkennung („Screening“) von Darmkrebs (colorectal cancer bzw. CRC) darzustellen. Diese Modelle werden von verschiedenen Richtliniengruppen wie der United States Preventative Services Task Force (USPSTF) und der American Cancer Society unterstützend bei der Entwicklung von Screening-Richtlinien genutzt. Bisher hat keines der bereits bestehenden Modelle zur Unterstützung von Richtlinien den methylierten Septin9-Bluttest (Epi proColon(R)) als Früherkennungsverfahren integriert. Das nun fertiggestellte Modell beinhaltet den Epi proColon(R)-Test und berücksichtigt ebenfalls die Schlüsselvariable der Testbefolgung. Die Testbefolgung ist ein entscheidendes Element für die Verbesserung der Teilnahmeraten beim CRC-Screening. Blutbasierte Tests versprechen eine Verbesserung der Teilnahmeraten am CRC-Screening durch dafür anspruchsberechtigte Personen, die bislang nicht regelmäßig gemäß der Richtlinien die Möglichkeiten zur Früherkennung wahrnehmen. Der Anteil dieser Personen liegt aktuell bei rund 35 % der Anspruchsberechtigten.

Über Epigenomics

Epigenomics AG ist ein Molekulardiagnostik-Unternehmen mit dem Fokus auf Bluttests zur Früherkennung von Krebs. Auf Basis seiner patentgeschützten Biomarker-Technologie für den Nachweis methylierter DNA entwickelt und vermarktet Epigenomics Bluttests für verschiedene Krebsindikationen mit hohem medizinischem Bedarf. Epigenomics‘ Hauptprodukt ist der Bluttest Epi proColon(R) zur Früherkennung von Darmkrebs. Epi proColon ist von der US-amerikanischen Zulassungsbehörde FDA zugelassen und wird in den USA, Europa, China und weiteren ausgewählten Ländern vermarktet. Für Epi proLung(R), einen Bluttest zur Erkennung von Lungenkrebs sowie für HCCBloodTest, einen Bluttest zur Erkennung von Leberkrebs, hat das Unternehmen das CE-Kennzeichen zur Vermarktung in Europa erhalten.

Für weitere Informationen besuchen Sie bitte www.epigenomics.com.

Kontakt:
Unternehmen
Epigenomics AG, Geneststrasse 5, 10829 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, E-Mail: contact@epigenomics.com

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, E-Mail: ir@epigenomics.com

Hinweis zu zukunftsgerichteten Aussagen

Diese Veröffentlichung enthält ausdrücklich oder implizit in die Zukunft gerichtete Aussagen, die die Epigenomics AG und deren Geschäftstätigkeit betreffen. Diese Aussagen beinhalten bestimmte bekannte und unbekannte Risiken, Unsicherheiten und andere Faktoren, die dazu führen können, dass die tatsächlichen Ergebnisse, die Finanzlage und die Leistungen der Epigenomics AG wesentlich von den zukünftigen Ergebnissen oder Leistungen abweichen, die in solchen Aussagen explizit oder implizit zum Ausdruck gebracht wurden. Epigenomics macht diese Mitteilung zum Datum der heutigen Veröffentlichung und beabsichtigt nicht, die hierin enthaltenen, in die Zukunft gerichteten Aussagen aufgrund neuer Informationen oder künftiger Ereignisse bzw. aus anderweitigen Gründen zu aktualisieren.

07.01.2019 Veröffentlichung einer Corporate News/Finanznachricht, übermittelt durch DGAP – ein Service der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap.de

Sprache:	Deutsch
Unternehmen:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Deutschland
Telefon:	+49 30 24345-0
Fax:	+49 30 24345-555
E-Mail:	ir@epigenomics.com
Internet:	www.epigenomics.com
ISIN:	DE000A11QW50
WKN:	A11QW5
Börsen:	Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart, Tradegate Exchange


Ende der Mitteilung	DGAP News-Service

02. Januar 2019

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG

02.01.2019 / 14:10
Dissemination of a Voting Rights Announcement transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer

Name:	Epigenomics AG
Street:	Geneststraße 5
Postal code:	10829
City:	Berlin Germany
Legal Entity Identifier (LEI):	549300X1C4U862NDLN97

2. Reason for notification

X	Acquisition/disposal of shares with voting rights
	Acquisition/disposal of instruments
	Change of breakdown of voting rights
	Other reason:

3. Details of person subject to the notification obligation

Legal entity: Morgan Stanley
City of registered office, country: Wilmington,Delaware, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.

Morgan Stanley & Co. LLC

5. Date on which threshold was crossed or reached:

27 Dec 2018

6. Total positions

	% of voting rights attached to shares (total of 7.a.)	% of voting rights through instruments (total of 7.b.1 + 7.b.2)	Total of both in % (7.a. + 7.b.)	Total number of voting rights pursuant to Sec. 41 WpHG
New	3.75 %	0.13 %	3.88 %	36021540
Previous notification	0.00 %	0.13 %	0.13 %	/

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)

ISIN	Absolute		In %
	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)	Direct (Sec. 33 WpHG)	Indirect (Sec. 34 WpHG)
DE000A11QW50	0	1350000	0.00 %	3.75 %
Total	1350000		3.75 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Voting rights absolute	Voting rights in %
Right of recall over securities lending agreements	at any time	at any time	45919	0.13 %
		Total	45919	0.13 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Cash or physical settlement	Voting rights absolute	Voting rights in %
				0	0.00 %
			Total	0	0.00 %

8. Information in relation to the person subject to the notification obligation

	Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X	Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name	% of voting rights (if at least 3% or more)	% of voting rights through instruments (if at least 5% or more)	Total of both (if at least 5% or more)
Morgan Stanley	%	%	%
Morgan Stanley Capital Management, LLC	%	%	%
Morgan Stanley Domestic Holdings, Inc.	%	%	%
Morgan Stanley & Co. LLC	3.75 %	%	%

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:

Proportion of voting rights	Proportion of instruments	Total of both
%	%	%

10. Other explanatory remarks:

Date

31 Dec 2018

02.01.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Epigenomics AG
	Geneststraße 5
	10829 Berlin
	Germany
Internet:	www.epigenomics.com


End of News	DGAP News Service

News & Investoren

Archive

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG gibt positive Ergebnisse eines Mikrosimulationsmodells bekannt

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Archiv

News-Kategorien

Medienkontakt